Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Sep. 30, 2024
Current assets:
Cash, cash equivalents and restricted cash	$ 53,889	$ 102,685
Accounts receivable	2,500	0
Available-for-sale securities, at fair value	499,046	578,276
Prepaid expenses	9,366	9,537
Other current assets	5,735	4,973
Total current assets	570,536	695,471
Property, plant and equipment, net	387,069	386,032
Intangible assets, net	8,137	8,562
Right-of-use assets	44,869	45,255
Other assets	3,083	4,482
Total Assets	1,013,694	1,139,802
Current liabilities:
Accounts payable	14,457	11,388
Accrued expenses	59,401	63,017
Accrued payroll and benefits	11,275	21,989
Lease liabilities	6,560	6,342
Credit facility	1,625	0
Other liabilities	440	432
Total current liabilities	93,758	103,168
Long-term liabilities:
Lease liabilities, net of current portion	109,296	111,027
Liability related to the sale of future royalties	346,776	341,361
Credit facility, net of current portion	407,789	393,183
Total long-term liabilities	863,861	845,571
Commitments and contingencies (Note 7)
Noncontrolling interest and stockholders’ equity:
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 125,572 and 124,376 shares	218	217
Additional paid-in capital	1,846,842	1,806,000
Accumulated other comprehensive income	4,137	4,750
Accumulated deficit	(1,798,608)	(1,625,523)
Total Arrowhead Pharmaceuticals, Inc. stockholders’ equity	52,589	185,444
Noncontrolling interest	3,486	5,619
Total noncontrolling interest and stockholders’ equity	56,075	191,063
Total Liabilities, Noncontrolling Interest and Stockholders’ Equity	$ 1,013,694	$ 1,139,802